Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC Immunotherapy Test
Cofactor Genomics, Inc., a clinical-stage company focused on advancing precision medicine through RNA decoding, has announced the publication of results from its PREDAPT clinical trial (NCT04510129) in head and neck squamous cell carcinoma (HNSCC). The study highlights the clinical validity…
Maravai to Acquire Officinae Bio’s DNA and RNA Business
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services, has announced an agreement to acquire the DNA and RNA business of Officinae Bio. This acquisition is expected to enhance Maravai and its subsidiary, TriLink BioTechnologies,…
GE HealthCare Launches Secondary Offering of 13.3 Million Shares
GE HealthCare Technologies Inc. (Nasdaq: GEHC) announced today the launch of a secondary underwritten public offering of 13,281,302 shares of its common stock (the “GEHC Shares”). The company is not selling any shares and will not receive any proceeds from…
BioIVT and KRISHGEN BioSystems Announce Exclusive South Asia Agreement
BioIVT, a global leader in biospecimen solutions and research support for drug and diagnostic development, has announced an exclusive partnership with KRISHGEN BioSystems. KRISHGEN, a prominent provider of life science research tools and services with over two decades of experience…
SBC Medical Group and MEDIROM Group Form Business Partnership
SBC Medical Group Holdings (California, USA, CEO: Aikawa Yoshiyuki), a provider of management support to medical institutions globally, has entered into a business partnership with MEDIROM Corporation (Headquarters: Minato-ku, Tokyo, CEO: Eguchi Koji). MEDIROM operates over 300 relaxation studios nationwide…
Guardant Health Reports Q3 2024 Results and Raises Revenue Guidance
Key Financial Highlights for Q3 2024: Recent Operating Highlights: CEO Comments: “We had another record quarter, driven by significant reimbursement tailwinds for Guardant360 and strong volume growth,” said Helmy Eltoukhy, co-founder and co-CEO. “With this momentum, we’re raising our revenue…
NovaBay Accepts Revised Offer from PRN and Increases Asset Purchase Price
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay”) announced today that it has accepted a revised offer from PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to raise the base purchase price for its eyecare business from $9.5 million to $11.5 million. The…
Minds + Assembly Expands Healthcare Platform by Partnering with BOLDSCIENCE
Minds + Assembly has announced its strategic partnership with BOLDSCIENCE, a full-service medical communications agency, to expand its world-class healthcare communications and commercialization platform. The collaboration will enhance Minds + Assembly’s ability to serve pharma, biotech, medical device, and digital…
Burjeel Holdings and Response Plus Launch $1M Human Energy Health Award
Burjeel Holdings and Response Plus Launch $1 Million Human Energy Health Award at ADIPEC 2024Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider…
Inocras and Summit Pharma Partner to Transform Clinical Genomics in Japan
Inocras Inc. (San Diego, CA; President & CEO: Jehee Suh) and Summit Pharmaceuticals International Corporation (Tokyo, Japan; President & CEO: Katsuya Okuyama) have signed a Memorandum of Understanding (MOU) to explore the commercialization of their whole genome sequencing (WGS) analysis…
Endologix Presents 36-Month DETOUR2 Study Results at 2024 VIVA
Endologix LLC, a global leader in medical devices for vascular disease, today revealed the final 36-month results of its DETOUR2 Study. The DETOUR System provides an innovative solution for treating complex peripheral arterial disease (PAD) by enabling physicians to bypass…
Fusion Orthopedics Wins USPTO Judgment Against Extremity Medical
Fusion Orthopedics, LLC has secured a major victory against Extremity Medical, LLC following a ruling by the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB). The PTAB invalidated 14 claims of U.S. Patent No. 11,298,166 (the ‘166…